Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial.


Journal

The Lancet. Rheumatology
ISSN: 2665-9913
Titre abrégé: Lancet Rheumatol
Pays: England
ID NLM: 101765308

Informations de publication

Date de publication:
Jun 2021
Historique:
pubmed: 27 4 2021
medline: 27 4 2021
entrez: 26 4 2021
Statut: ppublish

Résumé

No trials have tested multifaceted mental health interventions recommended by public health organisations during COVID-19. The objective of this trial was to evaluate the effect of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program on anxiety symptoms and other mental health outcomes among people vulnerable during COVID-19 owing to a pre-existing medical condition. The SPIN-CHAT Trial was a pragmatic, two-arm, parallel, partially nested, randomised, controlled trial (1:1 allocation to intervention or waitlist). Eligible participants with systemic sclerosis were recruited from the international SPIN COVID-19 Cohort. SPIN COVID-19 Cohort participants were eligible for the trial if they completed baseline measures and had at least mild anxiety symptoms, had not tested positive for COVID-19, and were not currently receiving mental health counselling. SPIN-CHAT is a 4-week (3 sessions per week) videoconference-based group intervention that provided education and practice with mental health coping strategies, and provided social support to reduce isolation. Groups included 6-10 participants. The primary outcome analysed in the intention-to-treat population was anxiety symptoms (PROMIS Anxiety 4a version 1.0) immediately post-intervention. This trial is registered with ClinicalTrials.gov, NCT04335279 and is complete. Of participants who completed baseline measures between April 9, 2020, and April 27, 2020, 560 participants were eligible and 172 participants were randomly assigned to intervention (n=86) or waitlist (n=86). Mean age was 55·0 years (SD 11·4 years), 162 (94%) were women, and 136 (79%) identified as White. In intention-to-treat analyses, the intervention did not significantly reduce anxiety symptoms post-intervention (-1·57 points, 95% CI -3·59 to 0·45; standardised mean difference [SMD] -0·22 points) but reduced symptoms 6 weeks later (-2·36 points, 95% CI -4·56 to -0·16; SMD -0·31). Depression symptoms were significantly lower 6 weeks post-intervention (-1·64 points, 95% CI -2·91 to -0·37; SMD -0·31); no other secondary outcomes were significant. No adverse events were reported. The intervention did not significantly improve anxiety symptoms or other mental health outcomes post-intervention. However, anxiety and depression symptoms were significantly lower 6 weeks later, potentially capturing the time it took for new skills and social support between intervention participants to affect mental health. Multi-faceted interventions such as SPIN-CHAT have potential to address mental health needs in vulnerable groups during COVID-19, yet uncertainty remains about effectiveness. Canadian Institutes of Health Research (CIHR; VR4-172745, MS1-173066); McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund; Scleroderma Canada, made possible by an educational grant for patient support programming from Boehringer Ingelheim; the Scleroderma Society of Ontario; Scleroderma Manitoba; Scleroderma Atlantic; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; Scleroderma Queensland; Scleroderma SASK; the Scleroderma Association of BC; and Sclérodermie Québec.

Sections du résumé

BACKGROUND BACKGROUND
No trials have tested multifaceted mental health interventions recommended by public health organisations during COVID-19. The objective of this trial was to evaluate the effect of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program on anxiety symptoms and other mental health outcomes among people vulnerable during COVID-19 owing to a pre-existing medical condition.
METHODS METHODS
The SPIN-CHAT Trial was a pragmatic, two-arm, parallel, partially nested, randomised, controlled trial (1:1 allocation to intervention or waitlist). Eligible participants with systemic sclerosis were recruited from the international SPIN COVID-19 Cohort. SPIN COVID-19 Cohort participants were eligible for the trial if they completed baseline measures and had at least mild anxiety symptoms, had not tested positive for COVID-19, and were not currently receiving mental health counselling. SPIN-CHAT is a 4-week (3 sessions per week) videoconference-based group intervention that provided education and practice with mental health coping strategies, and provided social support to reduce isolation. Groups included 6-10 participants. The primary outcome analysed in the intention-to-treat population was anxiety symptoms (PROMIS Anxiety 4a version 1.0) immediately post-intervention. This trial is registered with ClinicalTrials.gov, NCT04335279 and is complete.
FINDINGS RESULTS
Of participants who completed baseline measures between April 9, 2020, and April 27, 2020, 560 participants were eligible and 172 participants were randomly assigned to intervention (n=86) or waitlist (n=86). Mean age was 55·0 years (SD 11·4 years), 162 (94%) were women, and 136 (79%) identified as White. In intention-to-treat analyses, the intervention did not significantly reduce anxiety symptoms post-intervention (-1·57 points, 95% CI -3·59 to 0·45; standardised mean difference [SMD] -0·22 points) but reduced symptoms 6 weeks later (-2·36 points, 95% CI -4·56 to -0·16; SMD -0·31). Depression symptoms were significantly lower 6 weeks post-intervention (-1·64 points, 95% CI -2·91 to -0·37; SMD -0·31); no other secondary outcomes were significant. No adverse events were reported.
INTERPRETATION CONCLUSIONS
The intervention did not significantly improve anxiety symptoms or other mental health outcomes post-intervention. However, anxiety and depression symptoms were significantly lower 6 weeks later, potentially capturing the time it took for new skills and social support between intervention participants to affect mental health. Multi-faceted interventions such as SPIN-CHAT have potential to address mental health needs in vulnerable groups during COVID-19, yet uncertainty remains about effectiveness.
FUNDING BACKGROUND
Canadian Institutes of Health Research (CIHR; VR4-172745, MS1-173066); McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund; Scleroderma Canada, made possible by an educational grant for patient support programming from Boehringer Ingelheim; the Scleroderma Society of Ontario; Scleroderma Manitoba; Scleroderma Atlantic; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; Scleroderma Queensland; Scleroderma SASK; the Scleroderma Association of BC; and Sclérodermie Québec.

Identifiants

pubmed: 33899008
doi: 10.1016/S2665-9913(21)00060-6
pii: S2665-9913(21)00060-6
pmc: PMC8051930
doi:

Banques de données

ClinicalTrials.gov
['NCT04335279']

Types de publication

Journal Article

Langues

eng

Pagination

e427-e437

Informations de copyright

© 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

All authors have completed the ICMJE uniform disclosure form. LM reported personal fees from Actelion–Johnson & Johnson, grants from LFB, non-financial support from Octapharma, and non-financial support from Grifols, all outside the submitted work. All other authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. All authors declare no other relationships or activities that could appear to have influenced the submitted work.

Références

N Engl J Med. 2008 Jan 17;358(3):252-60
pubmed: 18199864
Public Health Nutr. 2010 Nov;13(11):1847-54
pubmed: 20196910
Psychol Med. 2019 Jun;49(8):1266-1274
pubmed: 30688184
J Clin Epidemiol. 2019 Nov;115:116-124
pubmed: 31330252
J Psychosom Res. 2020 Dec;139:110262
pubmed: 33070043
JAMA. 2018 Dec 25;320(24):2529-2530
pubmed: 30500053
J Psychosom Res. 2020 Dec;139:110271
pubmed: 33096402
Rheumatology (Oxford). 2018 Sep 1;57(9):1623-1631
pubmed: 29868924
Eur J Ageing. 2014 Mar 25;11(4):313-319
pubmed: 28804337
Eval Program Plann. 1979;2(3):197-207
pubmed: 10245370
J Psychosom Res. 2020 Aug;135:110132
pubmed: 32521358
Patient Educ Couns. 2013 Jun;91(3):271-9
pubmed: 23414831
Trials. 2019 Dec 12;20(1):717
pubmed: 31831073
Psychosom Med. 2016 Jul-Aug;78(6):716-27
pubmed: 27187854
J Nurs Scholarsh. 2012 Jun;44(2):136-44
pubmed: 22551013
BMJ. 1998 Jan 24;316(7127):285
pubmed: 9472515
Med Care. 2019 Nov;57(11):890-897
pubmed: 31415337
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
Psychotherapy (Chic). 2018 Dec;55(4):384-398
pubmed: 30335452
Int J Nurs Stud. 2016 Nov;63:101-111
pubmed: 27611093
Fam Pract. 2016 Dec;33(6):698-703
pubmed: 27411728
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852

Auteurs

Brett D Thombs (BD)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Department of Medicine, McGill University, Montreal, QC, Canada.
Department of Psychology, McGill University, Montreal, QC, Canada.
Department of Educational and Counselling Psychology, McGill University, Montreal, QC, Canada.
Biomedical Ethics Unit, McGill University, Montreal, QC, Canada.

Linda Kwakkenbos (L)

Department of Clinical Psychology, Behavioural Science Institute, Radboud University, Nijmegen, Netherlands.

Brooke Levis (B)

Centre for Prognosis Research, School of Medicine, Keele University, Staffordshire, UK.

Angelica Bourgeault (A)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.

Richard S Henry (RS)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.

Alexander W Levis (AW)

Department of Biostatistics, Harvard T H Chan School of Public Health, Cambridge, MA, USA.

Sami Harb (S)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.

Lydia Tao (L)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.

Marie-Eve Carrier (ME)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.

Laura Bustamante (L)

Department of Applied Human Sciences, Concordia University, Montreal, QC, Canada.

Delaney Duchek (D)

Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.

Laura Dyas (L)

Scleroderma Foundation, Michigan Chapter, Southfield, MI, USA.

Ghassan El-Baalbaki (G)

Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada.

Kelsey Ellis (K)

Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.

Danielle B Rice (DB)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Psychology, McGill University, Montreal, QC, Canada.

Amanda Wurz (A)

Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.

Julia Nordlund (J)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.

Maria Gagarine (M)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.

Kimberly A Turner (KA)

Department of Psychology, University of Ottawa, Ottawa, ON, Canada.

Nora Østbø (N)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.

Nicole Culos-Reed (N)

Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.
Department of Oncology, Cumming School of Medicine, Calgary, Canada.
Department of Psychosocial Resources, Tom Baker Cancer Centre, Alberta Health Services, Calgary, AB, Canada.

Shannon Hebblethwaite (S)

Department of Applied Human Sciences, Concordia University, Montreal, QC, Canada.

Scott Patten (S)

Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada.

Susan J Bartlett (SJ)

Department of Medicine, McGill University, Montreal, QC, Canada.
Research Institute, McGill University Health Centre, Montreal, QC, Canada.

John Varga (J)

University of Michigan, Ann Arbor, MI, USA.

Luc Mouthon (L)

Service de Médecine Interne, Centre de Référence Maladies Auto-immunes et Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
APHP-CUP, Hôpital Cochin, Université de Paris, Paris, France.

Sarah Markham (S)

Department of Biostatistics and Health Informatics, King's College London, London, UK.

Michael S Martin (MS)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Correctional Service of Canada, Ottawa, ON, Canada.

Andrea Benedetti (A)

Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Department of Medicine, McGill University, Montreal, QC, Canada.
Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, QC, Canada.

Classifications MeSH